Patient demographics by country (n=222 163)
| England | USA | p Value | |
|---|---|---|---|
| (n=25 235) | (n=196 928) | ||
| Year of diagnosis (%) | |||
| 2004 | 5378 (21.3) | 36 172 (18.4) | <0.001 |
| 2005 | 4959 (19.7) | 34 403 (17.5) | |
| 2006 | 5172 (20.5) | 40 531 (20.6) | |
| 2007 | 5009 (19.9) | 43 800 (22.2) | |
| 2008 | 4717 (18.7) | 42 022 (21.3) | |
| Age group (%) | |||
| 35–59 | 3620 (14.4) | 56 399 (28.6) | <0.001 |
| 60–64 | 4361 (17.3) | 40 287 (20.5) | |
| 65–69 | 6104 (24.2) | 42 439 (21.6) | |
| 70–74 | 6145 (24.4) | 33 912 (17.2) | |
| 75–79 | 5005 (19.8) | 23 891 (12.1) | |
| Ethnicity (%) | |||
| White | 17 924 (94.8) | 154 077 (80.4) | <0.001 |
| African/Caribbean | 571 (3.0) | 28 361 (14.8) | |
| Asian | 318 (1.7) | 8638 (4.5) | |
| Other | 105 (0.6) | 626 (0.3) | |
| Missing | 6317 | 5226 | |
| cT stage (%) | |||
| cT1 | 9374 (37.2) | 72 407 (36.8) | <0.001 |
| cT2 | 9538 (37.8) | 107 762 (54.7) | |
| cT3 | 5577 (22.1) | 15 482 (7.9) | |
| cT4 | 746 (3.0) | 1277 (0.7) | |
| Gleason score (%) | |||
| 2–6 | 10 909 (43.2) | 99 661 (50.6) | <0.001 |
| 7 | 9112 (36.1) | 75 247 (38.2) | |
| 8–10 | 5214 (20.7) | 22 020 (11.2) | |
| Modified NCCN risk (%) | |||
| Low risk | 6151 (24.4) | 45 045 (22.9) | <0.001 |
| Intermediate risk | 10 386 (41.2) | 118 074 (60.0) | |
| High risk | 8698 (34.5) | 33 809 (17.1) | |
| Treatment—all risk groups (%) | |||
| No definitive therapy | 15 583 (61.8) | 45 113 (22.9) | <0.001 |
| Definitive therapy | 9652 (38.2) | 151 815 (77.1) | |
| Treatment—low risk (%) | |||
| No definitive therapy | 3799 (61.8) | 17 516 (38.9) | <0.001 |
| Definitive therapy | 2352 (38.2) | 27 529 (61.1) | |
| Treatment—intermediate risk (%) | |||
| No definitive therapy | 5696 (54.8) | 21 999 (18.6) | <0.001 |
| Definitive therapy | 4690 (45.2) | 96 075 (81.4) | |
| Treatment—high risk (%) | |||
| No definitive therapy | 6088 (70.0) | 5598 (16.6) | <0.001 |
| Definitive therapy | 2610 (30.0) | 28 211 (83.4) | |
cT, clinical tumour; NCCN, National Comprehensive Cancer Network.